**EDITORIAL** 



## **EDITORIAL**

Pharmaco-genomics now is driving trend, resulting in changes to our pharmacy practice. There will be challenges to overcome, and among them, that the pharmaceutical industry is reluctant to potentially limit the use of its products, reimbursement for tests is still in flux, regulators and ethicists till date debates what the appropriate standards should be for testing, physicians are not certain what to do as clinical standards have yet to be determined and patients have not come together to demand access.

Emerging area that will greatly affect specialty pharmacy is molecular diagnostics and pharmaco-genomic testing. Genomic testing predicts how effective therapies will be for specific patients and their diseases, allowing health care professionals to target the right drug for the circumstances. Product targeting optimizes the patient's therapy, which in turn can drive treatment decisions. An excellent example is oncology patients; other future disease states that can benefit from pharmaco-genomics include rheumatoid arthritis, multiple sclerosis, oral contraceptives, depression, and osteoporosis. Wishing a healthy and disease free World.

Happy Reading.....

Dr. Arijit Mondal

Dept. of Pharmaceutical Chemistry
NSHM College of Pharmaceutical T

NSHM College of Pharmaceutical Technology, Kolkata

Indian Research Journal of Pharmacy and Science; 16(2018)1239;
Journal Home Page: https://www.irjps.in
DOI: 10.21276/irjps.2018.5.1.1